High frequency of brain metastases after adjuvant therapy for high‐risk melanoma

por Samlowski, Wolfram E., Moon, James, Witter, Merle, Atkins, Michael B., Kirkwood, John M., Othus, Megan, Ribas, Antoni, Sondak, Vernon K., Flaherty, Lawrence E.
Publicado 2017

A multi-center phase II study of high dose interleukin-2 sequenced with vemurafenib in patients with BRAF-V600 mutation positive metastatic melanoma

por Clark, Joseph I., Singh, Jatinder, Ernstoff, Marc S., Lao, Christopher D., Flaherty, Lawrence E., Logan, Theodore F., Curti, Brendan, Agarwala, Sanjiv S., Taback, Bret, Cranmer, Lee, Lutzky, Jose, Luna, Theresa L., Aung, Sandra, Lawson, David H.
Publicado 2018

Immune adverse events (irAEs) with adjuvant ipilimumab in melanoma, use of immunosuppressants and association with outcome: ECOG-ACRIN E1609 study analysis

por Tarhini, Ahmad A, Kang, Ni, Lee, Sandra J, Hodi, F Stephen, Cohen, Gary I, Hamid, Omid, Hutchins, Laura F, Sosman, Jeffrey A, Kluger, Harriet M, Eroglu, Zeynep, Koon, Henry B, Lawrence, Donald P, Kendra, Kari L, Minor, David R, Lee, Carrie B, Albertini, Mark R, Flaherty, Lawrence E, Petrella, Teresa M, Streicher, Howard, Sondak, Vernon K, Kirkwood, John M
Publicado 2021